In recent years, AKR1C3 has been implicated in the progression of prostate cancer, breast cancer, colon cancer and oropharyngeal squamous cell carcinoma, and contributes to therapeutic resistance in these types of cancers [13,14,15]. Here, AKR1C3 is linked to breast carcinoma.